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j ourna l homepage: www.eb iomed ic ine.comEditorialThe Need for Early Detection and Treatment in Alzheimer's DiseaseDespite its description over 100 years ago by German psychiatrist
Alois Alzheimer, there has been little effective translation of insights
on Alzheimer's disease (AD) pathobiology into effective treatments. As
of 2015, roughly 50 million people globally — most over the age of
65 years— have dementia, with AD accounting for 60–70% of cases. Al-
ready, AD is the sixth leading cause of death in the US and the leading
killer of women in the UK. As the population ages, AD is expected to af-
fect 135million people by 2050.Within the formal healthcare system in
the US, AD currently costs USD 236 billion per year, a number that does
not account for over 18 billion unpaid hours by those family and friends
voluntarily caring for AD patients. With June 2016, Alzheimer's Aware-
nessMonth, just behind us and the Alzheimer's Association Internation-
al Conference convening July 24–28, 2016, now seems a good time to
discuss the looming crisis of AD.
AD patients initially present with mild cognitive impairment
(MCI): occasional forgetting of details, misplacing of items, and
other symptoms that may be attributed to other factors like stress
or simply “aging”. Early-stage AD brings more noticeable memory
deﬁcits, such as forgetting familiar names and events, and confusion
in unfamiliar situations. Ultimately, late-stage AD patients may be
non-verbal or incoherent, have severe sleep and motor deﬁcits, and
become increasingly aggressive, paranoid, or unresponsive. An
emerging, frightening theme from recent studies is that by the time
cognitive impairment is noticed by a patient, their close relations,
or doctor, the cascade of events leading to full-blown AD may be ir-
reversible without a disease-modifying therapy. At present, only
ﬁve drugs are US FDA-approved for AD. None are disease-
modifying but instead are intended for symptom management,
with varying degrees of efﬁcacy.
It is clear that AD biomarkers are critical for catching the disease
early to allow for preventative interventions. The only deﬁnitive ge-
netic biomarkers for AD are mutations in amyloid precursor protein
(APP) or the presenilin enzymes 1 and 2 (PSEN1 and PSEN2). Each of
these genes contribute to the aberrant production of the peptide
Aβ40/42, which aggregates into the amyloid plaque deposits in
the brain that are a signature of AD. APP and PSEN mutations,
though, only account for a small fraction, roughly 5%, of early-
onset familial AD. A vast majority of AD cases are late-onset and
sporadic. Large-scale genome-wide association studies (GWAS)
are ongoing to identify risk and protective factors for AD. Hundreds
of genes have already been implicated, including the most signiﬁ-
cant APOEε4 variant, which confers a 5 to 15-fold higher risk for de-
veloping AD. As more GWAS hits emerge, it is the hope that they
may reveal other reliable mono- or oligogenic signatures of in-
creased risk for AD that will allow patients to enroll in early
interventions.http://dx.doi.org/10.1016/j.ebiom.2016.07.001
2352-3964/© 2016 The Author. Published by Elsevier B.V. This is an open access article underNon-genetic AD biomarkers are also being extensively explored.
It has been shown that a decade or more before MCI onset, increased
Aβ42 levels can be detected in patients' cerebrospinal ﬂuid (CSF).
Subsequent to Aβ42 detection in CSF, positron emission tomography
(PET) imaging can identify amyloid deposition in the brain. But am-
yloid is not the only culprit in AD pathology. Among other emerging
putative causes of AD — ranging from inﬂammation to metabolic
dysfunction — tau is another well-studied AD hallmark. This
microtubule-associated protein becomes hyperphosphorylated and
aggregates into neuroﬁbrillary tangles in AD patients' brains. Elevat-
ed tau levels are also seen in patients' CSF long before MCI onset, and
recent advances in tau PET tracers now allow detection of total or
misfolded tau in the brain. CSF sampling and PET imaging are not in-
expensive, routine, or comfortable procedures, however, and indeed
their predictive power is still somewhat controversial. These factors
have led to a growing ﬁeld screening for serum markers for pre-AD.
While it is still early days, proof-of-concept studies showing elevated
neuroﬁlament levels in pre-AD patients or the presence of Aβ42 au-
toantibodies are paving the way for future blood-based diagnostics
for early AD intervention.
There is no shortage of investigational AD drugs. However, be-
tween 2000 and 2012, while over 400 AD clinical trials were un-
dertaken, a recent study suggested that 99.6% of them ended in
failure (compared to anti-cancer drugs, with a roughly 80% failure
rate). One reason for such abysmal results may be that studies
were initiated too late in disease, after the cascade toward AD
has become inevitable. Herein lies the promise for pre-AD bio-
markers. Several ongoing clinical trials aim to prevent AD before
the disease can take root. One study is investigating the amyloid-
targeting antibody solanezumab in the Anti-Amyloid Treatment
in Asymptomatic Alzheimer's Disease (A4) trial, where patients al-
ready have appearance of amyloid plaques but are cognitively nor-
mal, hoping that removing plaques before the disease progresses
will be beneﬁcial. In another study (Generation trial), only patients
homozygous for the APOEε4 variant, who are asymptomatic but at
increased risk for developing AD, are being recruited for treatment
with either an investigational Aβ plaque-clearing immunotherapy
or an inhibitor targeting Aβ production. Because of the protracted
natural history of AD and relatively soft clinical end points (like
cognitive ability and day-to-day functional activity), these trials
are often exceedingly long, costly, and difﬁcult to interpret, requir-
ing considerable resolve from all stakeholders involved.
This issue of EBioMedicine includes a research article by Letronne
et al. on a human protein, ADAM30, which may affect amyloid depo-
sition in the brain but has not been well-studied because it is not nor-
mally expressed in the mouse, a common AD model organism. Thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
2 Editorialaccompanying commentary by Becker-Pauly and Pietrzik highlights
the need for alternative approaches to modeling AD to maximize
the likelihood for translation to the clinic. Likewise, ingenuitive ap-
proaches to discovering druggable targets, to validating biomarkers
for early diagnosis and as surrogate end points, and to optimizing
clinical trials for investigational AD therapies are desperately need-
ed. Only when all of these factors coalesce will we begin toeffectively solve the enigma of AD and change the lives of those hun-
dreds of millions of people directly and indirectly affected by this
tragic disease.
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